CA
NZ
UK
AU
IND
US
Exicure was founded on spherical nucleic acid (SNA) technology, developing gene-regulating therapies. That platform is no longer the story. Regulatory data now describe a company that "does not have significant operations" in its former sense, having pivoted after acquiring GPCR Therapeutics USA. The centerpiece …
Instil Bio originally built its identity around tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. After restructuring, the company shifted toward antibody-based oncologyAssetslicensed from China's ImmuneOnco. That strategy unraveled on January 6, 2026, when Instil's subsidiary, Axion Biosciences, announced it would discontinue clinical development of …
Tevogen Bio, which reports as Tevogen Inc., is developing allogeneic, off-the-shelf CD8+ cytotoxic T-cell therapies through a platform it calls ExacTcell. Its lead candidate, TVGN 489, targets high-risk COVID-19 and related indications such as long COVID, and the company has said a Phase 1 …
BiomX is a clinical-stage company developing natural and engineered phage therapies, viruses that selectively target and kill specific bacteria. Its lead candidate, BX004, is being studied in a Phase 2b trial for chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis, a difficult-to-treat …
Senti Biosciences is a clinical-stage company built around "logic-gated" cell and gene therapies, using engineered gene circuits designed to help therapies distinguish cancer cells from healthy tissue. Its most advanced asset, SENTI-202, is an allogeneic CAR-NK cell therapy aimed at acute myeloid leukemia and …
Core One Labs is a research-and-development company focused on psychedelic medicine, including biosynthetic production of psilocybin and delivery-technology platforms, alongside interests spanning natural health products and medical clinics. Its shares historically traded in Canada on theCanadian Securities Exchange (CSE)and in the U.S. over-the-counter market. …
Nano-X Imaging develops digital X-ray and medical-imaging technology, most notably the Nanox.ARC, a multi-source tomosynthesis system built around its cold-cathode digital X-ray source, along with AI-based image-analysis applications and a teleradiology arm. Through 2026 the company has focused on commercialising that hardware and software. …
22nd Century Group manufactures, distributes and sells proprietary reduced-nicotine tobacco products and provides contractManufacturingfor other tobacco brands. Its flagship is VLN, a cigarette engineered to contain far less nicotine, marketed under an FDA Modified Risk Tobacco Product framework as a harm-reduction option. Through 2026 …
GeoVax, based in Atlanta, develops vaccines and immunotherapies using its Modified Vaccinia Ankara (MVA) platform. On August 27, 2026, the company disclosed it had received a delisting determination from Nasdaq. According to its subsequent 8-K, GOVX's closing bid price stayed below the $1.00 minimum …
Reviva is a clinical-stage pharmaceutical company focused on brilaroxazine, an investigational treatment for schizophrenia and other central-nervous-system and inflammatory conditions. A notable structural development came on May 14, 2026, when Reviva's common stock moved from the Nasdaq Capital Market to the OTCQB Venture Market, …
Please wait processing your request...